Evidence you can cite.

Research Australia recommended that Treasury change proposed R&D Tax Incentive reforms that could cut support for medical research companies with long development timelines. It recommended the age limit removed, clinical trial support work to stay eligible, university spinouts protected, and more certainty for companies and investors.

Research Australia backed a new tax concession for investors in innovative start-ups and welcomed recent improvements. It recommended that the 15-year company age limit be removed or extended for slow-developing health businesses, and for clear rules so university and research institute spinouts can benefit.

Research Australia welcomed the inclusion of clinical research in the draft national hospital safety and quality standards. It recommended that a broader definition of research, board accountability for research, less duplicated paperwork, support for research staff and attention equity, rare diseases and AI, with the research provisions tested in the 2027 pilot.

Research Australia told a parliamentary committee that AI could improve health research and care, but only with national planning. It called for a national healthcare AI plan, a single health data strategy, sensible regulation, workforce training, public trust and equity built in from the start, including Indigenous control over Indigenous data.